
Amgen names senior VP of Business Development
pharmafile | March 21, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Amgen, David Piacquad
Amgen has confirmed the appointment of David Piacquad to the new position of senior vice president of its Business Development unit.
Piacquad will report directly to Robert Bradway, Amgen’s chairman and chief executive, and will be responsible for business development across the firm.
Piacquad is to lead a new organisation for the company that combines the previously separate Corporate Development and External Research & Development groups there.
Joining Amgen in June 2010 as vice president, Strategy & Corporate Development, he takes 26 years of business development and related experience to the role. He joined Schering-Plough in 2006 reaching the level of senior vice president, Business Development and Licensing.
Piacquad also joined Johnson & Johnson in 1984, holding a series of leadership roles in finance and business development.
“We are very pleased to have David step into this new role at Amgen,” said Bradway. “This change reflects Amgen’s increasing focus on harnessing external as well as internal innovation to ensure long-term growth for the company.”
Related Content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer
Amgen has announced that the US Food and Drug Administration (FDA) has approved Imdelltra (tarlatamab-dlle) …

Amgen opens new biomanufacturing facility in Ohio, US
Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. …

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial
AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …






